Addition of probenecid to penicillin-V therapy
Research type
Research Study
Full title
Addition of probenecid to penicillin-V therapy: an open label, cross-over study in healthy volunteers
IRAS ID
299581
Contact name
Timothy Rawson
Contact email
Sponsor organisation
Research Governance and Integrity Team (RGIT)
Eudract number
2021-002800-11
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study aims to build on previous work characterising the PK of penicillin-V to explore the potential impact of probenecid on PK-PD target attainment. Achievement of the aims of this study would provide data to support the design of experimental studies exploring the clinical impact of probenecid on treatment outcomes and also provide a rationale for exploration of probenecid’s effects on a larger number of beta-lactam antibiotics.
Hypothesis: Addition of probenecid to oral phenoxymethylpenicillin (penicillin-V) has a clinically relevant effect on pharmacokinetic-pharmacodynamic (PK-PD) target attainment.
Study design: Open label, cross-over study in healthy volunteers that will take place at Imperial Clinical Research Facility (CRF), Hammersmith Hospital, Du Cane Road, W12 0NN.
Healthy volunteers will attend two visits to Imperial CRF to undergo blood test analysis following dosing with either oral penicillin-V or oral penicillin-V plus probenecid. The effect of probenecid on penicillin-V serum concentration will be compared between both arms of the study.
Funding: This study is funded a British Infection Association (BIA) research grant.
REC name
London - Riverside Research Ethics Committee
REC reference
21/LO/0558
Date of REC Opinion
10 Aug 2021
REC opinion
Favourable Opinion